• News
  • SAN DIEGO
  • BioTech

Vista Partners updates coverage on Mast Therapeutics, maintains price target

San Francisco-based Vista Partners has updated coverage on Mast Therapeutics Inc. (NYSE: MSTX), a San Diego-based biopharmaceutical company, and maintains its 12-month price target of $2.25.

The announcement comes a day after Mast announced it had completed its acquisition of Aires Pharmaceuticals Inc.

Ross Silver, principal analyst at Vista Partners, said there has been considerable partnership and merger and aqcuisition activity for companies working on sickle cell disease.

In 2012, he noted, Selexys Pharmaceuticals Corp. entered into an agreement with Novartis Pharmaceuticals (NYSE: NVS). The agreement, he added, could reach up to $665 million. In October 2011, Pfizer (NYSE: PFE) signed a licensing deal with GlycoMimetics (Nasdaq: GLYC) that Silver said could be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties.

"GlycoMimetics, the first biotech IPO of 2014, currently trades at a market cap of around $225M," Silver wrote in a release, "whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial."

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Mast Therapeutics Inc.

Company Website

12390 El Camino Real Ste., 150
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
MSTX
0.5
  -0.01  
- 1.96%
703,889,000
0.63
0.38

Mast Therapeutics Inc. Executive(s):

Brian Culley

  • Chief Executive Officer

Patrick Keran

  • Chief Operating Officer, President

Brandi Roberts

  • Chief Financial Officer